Fig. 5.
Fig. 5. Immunoblot analysis. (A) The immunoblots probed with the rabbit antiglycocalicin antibodies. In lanes 1 and 2, 10 μg of the solubilized normal platelets was applied. In lanes 3 and 4, 20 μg of the solubilized patient's platelets was applied. Conditions were nonreduced (lanes 1 and 2) and reduced (lanes 3 and 4). (B) The immunoblots probed with the rabbit anti-GPIb/IX complex antibodies. Lane 5, normal platelets (10 μg protein) under reduced conditions; lane 6, the patient's platelets (20 μg protein) under reduced conditions. In the patient's platelets, the amount of normal nonreduced GPIb was decreased and the majority of GPIbα was not disulfide linked with GPIbβ. GPIbβ and GPIX were identified with normal electrophoretic mobilities.

Immunoblot analysis. (A) The immunoblots probed with the rabbit antiglycocalicin antibodies. In lanes 1 and 2, 10 μg of the solubilized normal platelets was applied. In lanes 3 and 4, 20 μg of the solubilized patient's platelets was applied. Conditions were nonreduced (lanes 1 and 2) and reduced (lanes 3 and 4). (B) The immunoblots probed with the rabbit anti-GPIb/IX complex antibodies. Lane 5, normal platelets (10 μg protein) under reduced conditions; lane 6, the patient's platelets (20 μg protein) under reduced conditions. In the patient's platelets, the amount of normal nonreduced GPIb was decreased and the majority of GPIbα was not disulfide linked with GPIbβ. GPIbβ and GPIX were identified with normal electrophoretic mobilities.

Close Modal

or Create an Account

Close Modal
Close Modal